The proposed acquisition of Merus is expected to meaningfully accelerate Genmab’s shift to a wholly owned model, expanding and diversifying the company’s revenue, driving sustained growth into the next decade and contributing to Genmab’s evolution into a biotechnology leader. The addition of petosemtamab, Merus’ lead asset, to Genmab’s promising late-stage pipeline is a compelling strategic fit with Genmab’s portfolio and aligns with Genmab’s expertise in antibody therapy development and commercialisation in oncology.
The team was led by Paul van der Bijl, with invaluable support from Nina Kielman, Frans Overkleeft, Stefan Wissing, Sybren de Beurs, Joppe Schoute, Ash Beesemer, Daniël Kuiper, Naud van Doorn, Ramon Pop, Max Morhman, Martin Plak, and Niels van Ham.